干眼治疗新药——利非司特滴眼液
A novel therapeutic for dry eye disease:lifitegrast ophthalmic solution
张然 1封昭 1张丽霞 2武丹蕾 3接英 4陈有信 5孙兴怀6
作者信息
- 1. 北京药学会,北京 100120
- 2. 中国中医科学院眼科医院 目系眼病科,北京 100040
- 3. 中国中医科学院广安门医院 眼科,北京 100053
- 4. 首都医科大学附属北京同仁医院 眼科,北京 100730
- 5. 中国医学科学院北京协和医学院北京协和医院 眼科,北京 100730
- 6. 上海复旦大学附属眼耳鼻喉科医院,上海 200031
- 折叠
摘要
利非司特是一种新型小分子整合素抑制剂,通过抑制淋巴细胞功能相关抗原1(LAF-1)与细胞间黏附分子1(ICAM-1)结合,抑制炎症级联反应,降低由T淋巴细胞介导的干眼炎性反应水平.该药2016年在美国上市,并于2018年纳入美国眼科协会(AAO)干眼治疗实践指南中.2023年12月被列入国家卫生健康委等6部门发布的《第三批鼓励仿制药品目录》名单中,2025年6月利非司特滴眼液获批在国内上市.本文对利非司特滴眼液的国内外研究资料进行系统梳理,从药效学、药动学、临床疗效以及安全性等不同的角度进行概述,旨在为临床安全合理用药提供参考.
Abstract
Lifitegrast is a novel small molecule integrin inhibitor that inhibits T-cell-mediated inflammation in dry eye disease(DED)by blocking the conformational activation of lymphocyte function-associated antigen-1(LFA-1)and its binding to intercellular adhesion molecule-1(ICAM-1).Lifitegrast ophthalmic solution were first approved in the United States in 2016 and was included in the American Academy of Ophthalmology(AAO)dry eye treatment practice guidelines in 2018.In December 2023,it was included in the list of the"Third Batch of Encouraged Generic Drugs"released by the National Health Commission and five other departments.In June 2025,lifitegrast ophthalmic solution were approved for listing in China.This article systematically reviews the domestic and international research data on lifitegrast ophthalmic solution from different perspectives such as pharmacology,pharmacokinetics,clinical efficacy,and safety,in order to provide a reference for the safe and rational use of the drug in clinical practice.
关键词
干眼/淋巴细胞功能相关抗原1/细胞间黏附分子1/利非司特滴眼液Key words
dry eye disease/lymphocyte function associated antigen-1/intercellular cell adhesion molecule-1/lifitegrast ophthalmic solution引用本文复制引用
出版年
2025
NETL
NSTL
万方数据